Pharma

Pharmalot By Ed Silverman

Ezekiel Emanuel on vaccines, Trump’s Covid-19 treatment, and what went wrong on the U.S. response

Pharmalot By Ed Silverman

Pharmalittle: J&J pauses Covid-19 vaccine trial; Moderna exec has earned $50 million from stock sales during pandemic

Pharmalot By Ed Silverman

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: White House pushes EUA for Regeneron and Lilly Covid-19 drugs; CMS scrambles to send drug cards

Pharmalot By Ed Silverman

Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO

Pharma By Matthew Herper

Virtual Event: The future of clinical trials

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca could profit from Covid-19 vaccine as of July; New England Journal slams Trump

Pharmalot By Ed Silverman

Pharmalittle: White House relents on FDA vaccine standards; Lilly claims Covid-19 treatment is effective

Health By Matthew Herper

Eli Lilly says its monoclonal antibody cocktail is effective in treating Covid-19

Pharmalot By Ed Silverman

Medical experts urge FDA to adopt stricter safety standards for Covid-19 vaccines

Pharmalot By Ed Silverman

Insulin in the U.S. cost up to 10 times more than in nearly three dozen other OECD countries

Pharma By Ed Silverman

STAT+ Conversations: An update from STAT’s Pharmalot

Pharmalot By Ed Silverman

Pharmalittle: White House halts new Covid-19 vaccine standards; GSK and Vir expanding coronavirus antibody trial

Pharmalot By Ed Silverman

What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Pharmalot By Ed Silverman

Supreme Court to review contentious state law governing pharmacy benefit managers

Pharmalot By Ed Silverman

Pharmalittle: Ransomware hits software firm supporting Covid-19 trials; White House objects to FDA vaccine standards

Pharmalot By Ed Silverman

South Africa and India urge WTO to waive IP rights, widen access to Covid-19 drugs and vaccines

The Pharmalot View By Ed Silverman

Oh, the irony! Trump may like to vilify drug makers, but now he needs them more than ever

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Trump at high risk of serious Covid-19 illness; Gilead to resume distribution of remdesivir

Pharmalot By Ed Silverman

Appeals court hands FTC a setback that invalidates its ability to claw back millions from AbbVie

Pharmalot By Ed Silverman

Pharmalittle: FDA extends probe into AstraZeneca Covid-19 vaccine; House committee blasts pharma CEOs over prices

Health Tech By Matthew Herper

Merck’s Roger Perlmutter joins board of AI drug discovery startup Insitro

Pharmalot By Ed Silverman

How is Covid-19 burnishing pharma’s reputation? An industry veteran weighs in

Pharma By Ed Silverman

New bill would create a subscription payment model to jumpstart antibiotic development

Matt's Take By Matthew Herper

Eager for a Covid vaccine, Trump now trusts drug companies he previously vilified

Pharmalot By Ed Silverman

For the first time, drug makers and PBMs must jointly face an insulin price fixing lawsuit

Pharmalot By Ed Silverman

Pharmalittle: Trump still insists a Covid-19 vaccine is ‘weeks away’; Regeneron antibody treatment shows promise